Table 5 Patterns of failure after gemcitabine-based neoadjuvant therapy in locally advanced pancreatic cancer
Metastatic/Recurrent Sites | Surgery n = 20 (%) | Non-surgery/n = 21 (%) |
|---|---|---|
Liver | 8 (40%) | 21 (100%) |
Peritoneum | 6 (30%) | 12 (57.1%) |
Others (bone, lung, soft tissue, brain) | 5 (25%) | 5 (23.8%) |
Loco-regional recurrence in resectable cases* | 1 (6%) | 0 |
Disease free | 3 (15%) | 0 |